Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan

2017 ◽  
Vol 28 (2) ◽  
pp. 103-111 ◽  
Author(s):  
Naoki Oishi ◽  
Tetsuo Kondo ◽  
Tadao Nakazawa ◽  
Kunio Mochizuki ◽  
Tomohiro Inoue ◽  
...  
Keyword(s):  
Braf V600e ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

scholarly journals Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas

2021 ◽  
Author(s):  
Tomoe Nakao ◽  
Michiko Matsuse ◽  
Vladimir Saenko ◽  
Tatiana Rogounovitch ◽  
Aya Tanaka ◽  
...  
Keyword(s):  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

scholarly journals Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer

Endocrinology ◽  
2019 ◽  
Vol 160 (10) ◽  
pp. 2328-2338 ◽  
Author(s):  
Tomasz Trybek ◽  
Agnieszka Walczyk ◽  
Danuta Gąsior-Perczak ◽  
Iwona Pałyga ◽  
Estera Mikina ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Response To Therapy ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Tumor Node Metastasis ◽  
Node Metastasis ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

Abstract In this study, we examined the relationship between coexisting BRAF V600E and TERT promoter mutations in papillary thyroid cancer (PTC) and response to therapy. PTC cases (n = 568) with known BRAF and TERT status, diagnosed from 2000 to 2012 and actively monitored at one institution, were reviewed retrospectively. Associations between BRAF V600E and TERT promoter mutations and clinicopathological features, Tumor-Node-Metastasis stage, initial risk, response to therapy, follow-up, and final disease outcome were assessed according to American Thyroid Association 2015 criteria and the American Joint Committee on Cancer/Tumor-Node-Metastasis (8th edition) staging system. Median follow-up was 120 months. TERT promoter mutations (any type) were detected in 13.5% (77/568) of PTC cases with known BRAF status. The C228T and C250T TERT hotspot mutations were found in 54 (9.5%) and 23 (4%) patients, respectively, and 22 other TERT promoter alterations were identified. Coexisting BRAF V600E and TERT hotspot promoter mutations were detected in 9.5% (54/568) of patients, and significantly associated with older patient age (P = 0.001), gross extrathyroidal extension (P = 0.003), tumor stage pT3-4 (P = 0.005), stage II to IV (P = 0.019), intermediate or high initial risk (P = 0.003), worse than excellent response to primary therapy (P = 0.045), recurrence (P = 0.015), and final outcome of no remission (P = 0.014). We conclude that coexisting BRAF V600E and TERT mutations in patients with PTC are associated with poor initial prognostic factors and clinical course and may be useful for predicting a worse response to therapy, recurrence, and poorer outcome than in patients without the above mutations.

Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAFV600E Mutation–Prevalent Population

Thyroid ◽  
2016 ◽  
Vol 26 (7) ◽  
pp. 901-910 ◽  
Author(s):  
Seung Eun Lee ◽  
Tae Sook Hwang ◽  
Yoon-La Choi ◽  
Hye Seung Han ◽  
Wan Seop Kim ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Thyroid Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

scholarly journals Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans

2020 ◽  
Vol 54 (4) ◽  
pp. 310-317
Author(s):  
Sue Youn Kim ◽  
Taeeun Kim ◽  
Kwangsoon Kim ◽  
Ja Seong Bae ◽  
Jeong Soo Kim ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Low Frequency ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

scholarly journals BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0153319 ◽  
Author(s):  
Jian Sun ◽  
Jing Zhang ◽  
Junliang Lu ◽  
Jie Gao ◽  
Xinyu Ren ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf V600e ◽  
Chinese Patients ◽  
Papillary Thyroid ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer

JAMA Oncology ◽  
2017 ◽  
Vol 3 (2) ◽  
pp. 202 ◽  
Author(s):  
Rengyun Liu ◽  
Justin Bishop ◽  
Guangwu Zhu ◽  
Tao Zhang ◽  
Paul W. Ladenson ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Papillary Thyroid Cancer ◽  
Mortality Risk ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

scholarly journals Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations

Oncotarget ◽  
2017 ◽  
Vol 8 (65) ◽  
pp. 108946-108957 ◽  
Author(s):  
Soo Yeon Hahn ◽  
Tae Hyuk Kim ◽  
Chang Seok Ki ◽  
Sun Wook Kim ◽  
Soohyun Ahn ◽  
...  
Keyword(s):  
Clinicopathological Features ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations
Sign in / Sign up

Export Citation Format

Share Document